Regeneron Pharmaceuticals Inc (REGN)

690.88
+4.86(+0.71%)
After Hours
700.00
+9.12(+1.32%)
- Real-time Data
  • Volume:
    560,772
  • Day's Range:
    684.70 - 699.63
  • 52 wk Range:
    492.20 - 747.42

REGN Overview

Prev. Close
686.02
Day's Range
684.7-699.63
Revenue
16.51B
Open
689
52 wk Range
492.2-747.42
EPS
70.56
Volume
560,772
Market Cap
74.44B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
642,348
P/E Ratio
9.72
Beta
0.23
1-Year Change
38.72%
Shares Outstanding
107,746,194
Next Earnings Date
Aug 04, 2022
What is your sentiment on Regeneron Pharma?
or
Market is currently closed. Voting is open during market hours.

Regeneron Pharmaceuticals Inc News

  • Regeneron Tops Q1 EPS by $1.45
    • ByInvesting.com-

    Regeneron (NASDAQ:REGN) reported Q1 EPS of $11.49, $1.45 better than the analyst estimate of $10.04. Revenue for the quarter came in at $2.97 billion versus the consensus estimate...

Regeneron Pharmaceuticals Inc Analysis

Regeneron Pharmaceuticals Inc Company Profile

Regeneron Pharmaceuticals Inc Company Profile

Employees
9766

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong SellBuyStrong BuyStrong BuyStrong Buy
  • 😃
    0
    • best opportunity in this market
      0
      • only take long positions .
        0
        • huge earnings beat!
          0
          • Whats happening
            0
            • Fall
              0
            • Most of sales in this quarters are from COVID, and competion announced results
              0
          • Acquiring Inovio will propel REGN closer to COVID 19 vaccine and clear path to 1K a share.
            3
            • This should boost Inovio. Time to pile up.
              2
              • hi
                1
                • A lot undervalued
                  0
                  • Regn sets to reach its peak👍
                    0